Matrixyl 3000 Serum: Ingredient Identity, Concentration and Supplier Questions

Start with the exact commercial grade

Matrixyl 3000 is a trade-family ingredient associated with a system containing Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7. Buyers should confirm trademark ownership and the exact authorized grade rather than using “Matrixyl” as a generic synonym for every blend of those peptides.

INCI composition and carrier

A commercial stock solution can include water, humectants or other solvents, preservatives and the peptide components. Request the complete INCI list in order, the product code and the supplier specification. This information affects label drafting, preservation, viscosity and total formula water.

Percentages can be misleading

A statement such as “10% Matrixyl 3000” may refer to ten percent of a supplier blend—not ten percent pure peptide. Marketing, formulation and purchasing teams must use the same concentration basis. The RFQ should distinguish stock-solution dose, peptide active content and any assay value shown on the COA.

Evidence and claim translation

Published research on palmitoyl pentapeptide or other palmitoylated peptides is relevant background but is not automatically evidence for a different two-peptide blend or finished serum. Obtain the commercial grade’s technical dossier and review whether data support ingredient-level wording or the planned finished-product claim.

Processing and stability

Confirm recommended pH, addition temperature, mixing sequence, storage and incompatibilities. Add the peptide system consistently at lab and pilot scale, then monitor color, odor, pH, viscosity and relevant chemical markers. If a formula fails, investigate the complete system rather than assuming the peptide itself is unstable.

Supplier qualification

Compare vendors on identity traceability, manufacturing source, specification, batch COA, SDS, change-notification policy, sample-to-bulk consistency, MOQ and lead time. A lower per-kilogram quote may have a different concentration or document scope, so normalize cost to active basis and usable finished-formula yield.

Brief for a finished Matrixyl serum

Define target texture, companion peptides, humectants, fragrance policy, packaging, fill size, market and claim language. Approve a lab sample, filled-pack stability protocol and artwork wording before commercial production. This creates a credible Matrixyl 3000 serum without relying on an unexplained percentage headline.

Selected research for further reading

These sources provide background; they do not substitute for finished-product substantiation.

• Palmitoyl pentapeptide clinical study